NEWS

Renatus Inc., a pharmaceutical company focused on developing cholesterol metabolism modulators, was selected for the Merck’s 2024 Advance Biotech Grant Program – Korea. The Merck’s Advance Biotech Grant Program has recognized innovative biotechnology companies worldwide since 2014.

Renatus Inc., a pharmaceutical company focused on developing cholesterol metabolism modulators, today announced the registration of a U.S. patent No. 11931376 entitled “METHODS FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE.”

Renatus, a pharmaceutical company developing cholesterol modulators for the treatment of cholesterol-driven diseases, announced that it was introduced on Pax Economy TV's 'Close-Up of Business', which introduces promising small businesses based in South Korea.

Renatus presented data on RN-005, a cholesterol metabolism modulator, in preclinical chronic kidney disease models at the 2023 Scale-up Challenge Lab Conference.

Renatus, Carbohyde sign MOU to co-develop novel cholesterol modulators for CNS disease applications.

Renatus was selected for the Scale-Up Challenge Lab program by Incheon Startup Park.

Renatus has been granted a key patent for novel cyclodextrins for the treatment of cholesterol-driven diseases by Korea Intellectual Property Office (KIPO).

Renatus was selected for the HBIC program by Korea Health Industry Development Institute (KHIDI).

Renatus was selected for the Startup-Focused University Program by Ministry of SMEs and Startups.

Renatus was selected for the Smart-X Bio program by Incheon Startup Park to support innovative bio startups.

Renatus was selected for the HBIC program by Korea Health Industry Development Institute (KHIDI).

RENATUS LAUNCHES ITS OFFICIAL WEBSITE